Search results for "Ceta"

showing 10 items of 1865 documents

Polymorphonuclear leukocyte membrane fluidity before and after activation in subjects with insulin resistance.

2000

The aim of this research was the evaluation of polymorphonuclear leukocyte (PMN) membrane fluidity in subjects with insulin resistance. Insulin sensitivity, in fact, may be influenced by plasma membrane fluidity. We enrolled 19 subjects with insulin resistance previously demonstrated during an euglycemic hyperinsulinemic clamp. PMN membrane fluidity was studied by labeling intact cells with the fluorescent probe 1-[4-(trimethylamino)phenyl]-6-phenyl-1,3,5-hexatriene and calculating the fluorescence polarization degree. The measurement was made before and after incubation of PMNs with two activating agents: 4-phorbol 12-myristate 13-acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (…

AdultMalemedicine.medical_specialtyAdolescentMembrane FluidityNeutrophilsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentIn Vitro TechniquesNeutrophil Activationchemistry.chemical_compoundEndocrinologyInsulin resistanceReference ValuesDiabetes mellitusInternal medicineHyperinsulinismGlucose IntoleranceInternal MedicinemedicineMembrane fluidityHumansObesityChildPancreatic hormoneChemistryInsulinhemic and immune systemsGeneral MedicineN-Formylmethionine leucyl-phenylalanineGlucose clamp techniqueMiddle Agedmedicine.diseaseN-Formylmethionine Leucyl-PhenylalanineEndocrinologyDiabetes Mellitus Type 2Glucose Clamp TechniqueTetradecanoylphorbol AcetateFemaleInsulin ResistanceHyperinsulinismActa diabetologica
researchProduct

Stimulus-Dependent Increased Generation of Oxygen Intermediates in Monocytes and Polymorphonuclear Leukocytes in Psoriasis

1985

Based on recent findings indicating increased respiratory burst activity of monocytes (M phi) and polymorphonuclear leukocytes (PMN) in psoriasis upon stimulation with zymosan particles, we examined the question of whether incubation with various stimuli always results in augmented oxidative metabolism in psoriatic phagocytes. We compared M phi and PMN isolated from the peripheral blood of 12 patients with psoriasis and 12 control individuals. We measured the generation of oxygen intermediates of resting and stimulated M phi and PMN by luminol-enhanced chemiluminescence. The stimulants applied were: (1) aggregated immunoglobulin (aggIg), (2) zymosan, (3) zymosan opsonized with autologous se…

AdultMalemedicine.medical_specialtyAdolescentNeutrophilsStimulationDermatologyGranulocyteBiochemistryMonocyteschemistry.chemical_compoundInternal medicinePsoriasisConcanavalin AmedicineHumansPsoriasisMolecular BiologyAgedbiologyChemistryMonocyteZymosanZymosanhemic and immune systemsCell BiologyMiddle Agedmedicine.diseaseStimulation ChemicalRespiratory burstOxygenEndocrinologymedicine.anatomical_structureConcanavalin ATetradecanoylphorbol AcetateLuminescent MeasurementsImmunologybiology.proteinTetradecanoylphorbol AcetateFemaleJournal of Investigative Dermatology
researchProduct

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct

Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease

1980

The cardiovascular effects of a single i.v. dose (2 mg/kg over 5 min) of lorcainide were studied in 14 patients with heart disease. In the haemodynamic part of the study (6 patients), the aortic and pulmonary systolic, diastolic and mean pressures, left ventricular systolic and end-diastolic pressures, cardiac output and the rate of rise of left ventricular pressure were measured before and for 30 min after administration of the drug. Lorcainide produced a slight and short-lasting decrease in the aortic and pulmonary systolic pressures, and all other pressure values remained unchanged. The cardiac output and systemic vascular resistance were not altered by lorcainide. It consistently depres…

AdultMalemedicine.medical_specialtyCardiac outputTime FactorsHeart DiseasesHeart diseaseBenzeneacetamidesDiastoleHemodynamicsBlood PressureLorcainidePiperidinesInternal medicinemedicineHumansPharmacology (medical)Cardiac OutputAgedPharmacologyEjection fractionbusiness.industryHeartGeneral MedicineMiddle Agedmedicine.diseaseMyocardial Contractionmedicine.anatomical_structureAnesthesiaVascular resistanceVentricular pressureCardiologyFemaleVascular ResistancebusinessAnti-Arrhythmia Agentsmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

2003

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

AdultMalemedicine.medical_specialtyDiabetic neuropathyGabapentinAdolescentCyclohexanecarboxylic Acidsmedicine.medical_treatmentAcetatesGeneticsmedicineHumansBrief Pain InventoryAminesGenetics (clinical)gamma-Aminobutyric AcidPain Measurementbusiness.industryVascular diseaseEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryAnticonvulsantTreatment OutcomeAnesthesiaNeuropathic painFabry DiseaseNeuralgiaAnticonvulsantsGabapentinbusinessmedicine.drugJournal of inherited metabolic disease
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

Infected osteoradionecrosis of the mandible: follow-up study suggests deterioration in outcome for patients with Actinomyces-positive bone biopsies.

2006

Abstract Infected osteoradionecrosis (IORN) is one of the major complications of oral cancer radiotherapy. Recent studies showed a high prevalence of Actinomyces in IORN. In this study, the clinical follow up of IORN patients ( n  = 25; 20 male, 5 female) with regard to Actinomyces detection in the mandible was analyzed. Within 1.6–119 months of follow up, disease control was achieved in almost 90% of the patients with Actinomyces -negative bone biopsies, but only in 25% of the Actinomyces -positive group. The presence of Actinomyces was associated with a significantly higher risk of treatment failure ( P  = 0.004; Fisher's exact test). This held true when the data were controlled for ‘exte…

AdultMalemedicine.medical_specialtyOsteoradionecrosismedicine.medical_treatmentMandibleGastroenterologyActinomycosisInternal medicineBiopsymedicineActinomycesHumansMandibular DiseasesAgedbiologymedicine.diagnostic_testbusiness.industryMandibleFollow up studiesActinomycetaceaeMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryRadiation therapyExact testLogistic ModelsTreatment OutcomeOtorhinolaryngologyOsteoradionecrosisSurgeryFemaleOral SurgerybusinessActinomycesFollow-Up StudiesInternational journal of oral and maxillofacial surgery
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Experiences of a Poison Center Network with Renal Insufficiency in Acetaminophen Overdose: An Analysis of 17 Cases

2005

Renal insufficiency is less common than liver failure in acetaminophen overdose but renal tubular damage occurs even in the absence of hepatotoxicity. Data published on this topic are rare consisting mostly of case reports or reports in a small number of patients. Presently, a larger number of patients with renal insufficiency associated with acetaminophen overdose should be analyzed using a multicenter approach.Retrospective analysis of patients with acetaminophen-related nephrotoxicity reported to a poison center network from 1995 to 2003. Renal insufficiency was defined as elevated serum creatinine of more than double of the normal range (2.4 mg/dL [212 micromol/L]). Patients were classi…

AdultMalemedicine.medical_specialtyPediatricsPoison Control Centersacetaminophen overdoseAdolescentInjury controlPoison controlurologic and male genital diseasesToxicologyGermanymedicineAdverse Drug Reaction Reporting SystemsHumansRenal InsufficiencyAntipyreticIntensive care medicineAcetaminophenAgedbusiness.industryLiver failureGeneral MedicineAnalgesics Non-Narcoticmedicine.diseaseAcetaminophenFemaleDrug OverdoseDrug intoxicationbusinessmedicine.drugKidney diseaseClinical Toxicology
researchProduct

Quantitative computed tomography-assisted osteodensitometry of the pelvis after press-fit cup fixation: a prospective ten-year follow-up.

2011

Background: As a follow-up of a previously reported three-year study, we analyzed the periprosthetic acetabular cortical and cancellous bone density changes at ten years after implantation of a press-fit cup. Methods: Prospective clinical, radiographic, and quantitative computed tomography examinations were performed within ten days and at mean periods of one, three, and ten years after total hip arthroplasty with a press-fit cup, a femoral stem with a tapered design, and alumina-alumina pairing. Periacetabular cortical and cancellous bone density (mg CaHA/mL) in the cranial, ventral, and dorsal regions about the cup were measured for twenty-four hips in vivo. Results: All acetabular cups s…

AdultMalemedicine.medical_specialtyRadiographyArthroplasty Replacement HipPeriprostheticOsteoarthritis HipPelvisBone DensitymedicineHumansOrthopedics and Sports MedicineProspective StudiesQuantitative computed tomographyFixation (histology)Agedmedicine.diagnostic_testbusiness.industryAcetabulumGeneral MedicineMiddle Agedmedicine.anatomical_structureTreatment OutcomeHip boneOrthopedic surgerySurgeryCortical boneFemalesense organsRadiologyBone RemodelingHip ProsthesisNuclear medicinebusinessTomography X-Ray ComputedCancellous boneFollow-Up StudiesThe Journal of bone and joint surgery. American volume
researchProduct